Pretreatment ctDNA levels and molecular responses are independently prognostic of outcomes in aggressive lymphomas. These risk factors could potentially guide future personalized risk-directed approaches.

No abstract

Highlights d Current cancer biomarkers are obtained throughout a disease or treatment course d Prognostic biomarkers can be integrated over time similar to ''win probability'' models d Dynamic risk profiling produces a personal risk model and outperforms traditional methods d Dynamic risk profiling can potentially inform personalized therapy selection

No abstract

Lymphatic abnormalities represent an important but unrecognized problem in patients with leg cellulitis.